Evidence map›Paper›PMID 37830594›Full record

ArticleCells2023

New

Loka Reddy Velatooru, Cheng Hui Hu, Pedram Bijani, Xiaohong Wang, Pierr Bojaxhi, Hao Chen, Madeleine Duvic, Xiao Ni

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. "Next top" mouse models advancing CTCL research.Frontiers in cell and developmental biology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Loka Reddy VelatooruDepartment of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0003-1451-6879
Cheng Hui HuDepartment of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Pedram BijaniDepartment of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Xiaohong WangDepartment of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Pierr BojaxhiDepartment of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Hao ChenDepartment of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0003-0857-7405
Madeleine DuvicDepartment of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Xiao NiDepartment of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-0154-446X
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

Constitutively activated tyrosine kinase JAK3 is implicated in the pathogenesis of cutaneous T-cell lymphomas (CTCL). The mechanisms of constitutive JAK3 activation are unknown although a

Indexed as

Lymphoma, T-Cell, CutaneousOncogene Proteins, FusionSezary SyndromeSkin NeoplasmsAnimalsHumansInsulinJanus Kinase 3MiceProteinsRNA, Guide, CRISPR-Cas SystemsRNA, Small InterferingInsulinJAK3 protein, humanJanus Kinase 3Leydig insulin-like proteinOncogene Proteins, FusionProteinsRNA, Guide, CRISPR-Cas SystemsRNA, Small Interferingcutaneous T-cell lymphomasINSL3JAK3mycosis fungoidesRNA interferenceSézary syndrome

Identifiers

PMID37830594
PMCPMC10572011
OpenAlexW4387185995

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.